Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, XI and Y are defined herein, which are suitable for the treatment of a disease chosen from rheumatoid arthritis, systemic lupus erythromatosis, scleroderma, asthma, allergic rhinitis, allergic eczema, B cell lym...

Full description

Saved in:
Bibliographic Details
Main Authors Disalvo Darren Todd, Zindell Renee M, Bentzien Joerg Martin, Horan Joshua Courtney, Mao Wang, Soleymanzadeh Fariba, Shen Yue, Bosanac Todd, Berry Angela Kay, Mao Can, Liang Shuang, Burke Michael Jason
Format Patent
LanguageEnglish
Published 23.02.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, XI and Y are defined herein, which are suitable for the treatment of a disease chosen from rheumatoid arthritis, systemic lupus erythromatosis, scleroderma, asthma, allergic rhinitis, allergic eczema, B cell lymphoma, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, graft versus host disease, psoriatic arthritis, ankylosing spondylitis and uveitis.
Bibliography:Application Number: NZ20130703607